BACKGROUND Shenqi Jiangtang Granules (SQJT), a traditional Chinese patent medicine, have long been prescribed for type II diabetes mellitus. Increasing evidence suggests that SQJT has cardioprotective effects; however, its mechanisms in diabetic cardiomyopathy (DCM), particularly regarding ferroptosis, remain unclear. We hypothesized that SQJT protects against DCM by inhibiting ferroptosis via the dihydroorotate dehydrogenase (DHODH)/coenzyme Q (CoQ) signaling pathway. AIM To elucidate the mechanism through which SQJT attenuates ferroptosis in DCM. METHODS Active constituents of SQJT were obtained from previous mass spectrometry analyses. Potential targets were predicted using network pharmacology, protein-protein interaction, molecular docking, and dynamics simulation. Cell viability, death, and ferroptosis markers were assessed in high glucose/lipid-induced H9C2 cells. Intracellular iron, malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione (GSH), and reactive oxygen species (ROS) levels were measured, and mitochondrial morphology was examined by MitoTracker staining. The expression of DHODH/CoQ pathway components was analyzed by reverse transcription-quantitative PCR and Western blotting, and pathway dependence was confirmed using the DHODH inhibitor brequinar (BRQ). RESULTS The SQJT-DCM-ferroptosis network identified 16 intersecting targets, with DHODH as the primary candidate. SQJT significantly improved cell viability and attenuated ferroptosis. Specifically, treatment with 6% SQJT reduced intracellular free iron levels by 61.8% and lipid peroxidation (MDA) levels by 55.9% (all P < 0.001). Furthermore, SQJT restored antioxidant enzyme activities (SOD and GSH-PX) by over 100%, while maintaining mitochondrial membrane integrity and reducing the proportion of ROS-positive cells from 51.6% to 11.8%. These protective effects, mediated via the DHODH/CoQ signaling axis, were significantly abolished by BRQ. CONCLUSION SQJT alleviates ferroptosis and oxidative stress, potentially through modulation of the DHODH/CoQ pathway, while preserving mitochondrial integrity and enhancing cardiomyocyte survival, suggesting its therapeutic potential in DCM. However, the mechanistic findings were based on pharmacological inhibition rather than genetic validation. Therefore, further genetic and in vivo studies are needed.